SAM
KNSA icon

Silvercrest Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Silvercrest Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5M Sell
114,289
-12,120
-10% -$537K 0.04% 408
2025
Q4 		$5.21M Buy
126,409
+149
+0.1% +$5.98K 0.04% 424
2025
Q3 		$4.9M Buy
+126,260
New +$4.1M 0.03% 428

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Silvercrest Asset Management's KNSA Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 9.6% in Q1 2026, selling an estimated $537K and leaving 114,289 shares worth $5.5M. The position accounts for 0.04% of the portfolio, ranked #408.

Silvercrest Asset Management first reported a position in KNSA in Q3 2025 and has held it in 3 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Silvercrest Asset Management held 114,289 shares of Kiniksa Pharmaceuticals worth $5.5M as of Q1 2026.
  • Silvercrest Asset Management sold 12,120 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $537K.
  • Kiniksa Pharmaceuticals made up 0.04% of Silvercrest Asset Management's portfolio in Q1 2026, its #408 holding.
  • Silvercrest Asset Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.